Findings from three studies conducted by the U.S. Food and Drug Administration (FDA) confirm that the way information is conveyed and displayed in printed drug advertising affects consumer understanding of prescription medications.
Abbott and Biotest AG announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis.
A study by a team from the Texas Biomedical Research Institute comparing hepatitis C virus (HCV) with hepatitis A virus (HAV) infections in chimpanzees sheds light on the nature of the body's immune response to these viruses.
Genentech announced a Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
Scripps Research Institute scientists have discovered new elements of the blood clot-formation process that could lead to better drugs for preventing heart attacks and other clot-related conditions.
Medidata Solutions, a global provider of SaaS-based clinical development solutions, agreed to acquire Clinical Force, a pioneer in providing SaaS-based clinical trial management systems.
Redd&Whyte is launching the Preddator 4-channel system. The S4 has four dispensing channels for more efficient microplate filling and contains a number of enhancements to its software.
Uniqsis Ltd is introducing a gas addition module for the Uniqsis FlowSyn and other continuous flow reactors. The new module enables fast, controllable pre-saturation of liquid reagents with a wide range of gases.
Scientists have developed a method to make proteins form crystals using "smart materials" that remember the shape and characteristics of the molecule. This new technique should help scientists work out the structure of drug targets.
Seaside Therapeutics, Inc. initiated a randomized, double-blind, placebo-controlled Phase 2b study to evaluate the effects of STX209 on social impairment in children, adolescents, and adults with autism spectrum disorders.
Watson Pharmaceuticals Inc. is seeking Food and Drug Administration approval to sell a generic version of GlaxoSmithKline's enlarged-prostate treatment Avodart, the drugmaker said.
An international research team has developed a groundbreaking treatment for cystic fibrosis sufferers. The new drug will benefit sufferers who have the 'Celtic Gene', a genetic mutation which is particularly common in Ireland.
The Food and Drug Administration said it approved the first generic versions of Johnson & Johnson's antibiotic Levaquin, which treats bacterial infections that cause bronchitis or pneumonia.
European Union regulators have approved the first once-per-week diabetes medication. Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said they received marketing approval for Bydureon.